Onkologie. 2014:8(6):269-274

Overview of the diagnostics and treatment of the cervical cancer

Josef Chovanec, Monika Náležinská
Oddělení gynekologické onkologie, MOÚ Brno

Three types of standard treatment of cervical cancer are used: surgery, radiation therapy, chemotherapy. New types of treatment are

being tested in clinical trials.Treatment decisions should be individualized and based on prognostic factors including the stage of the

disease, age, medical condition of the patient, histological type and grade of tumor and lymph nodes status.

Keywords: cervical cancer, diagnostics, therapy

Published: December 15, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Chovanec J, Náležinská M. Overview of the diagnostics and treatment of the cervical cancer. Onkologie. 2014;8(6):269-274.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Dušek L, Mužík J, Kubásek M, et al. Epidemiologie zhoubných nádorů v České republice [online]. Masarykova univerzita, [2005], [cit. 2014-8-10]. Dostupný z WWW: http://www. svod.cz. Verze 7.0 [2007].
    2. Cibula D, Petrželka L, et al. Onkogynekologie, Grada Publishing, Praha, I. vydání, 2009: 616.
    3. De Sanjose S, Quint WG, Alemany L, et al. Human papillomavirus genotypeattribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol. 2010; 11: 1048-1056. Go to original source... Go to PubMed...
    4. Tachezy R, Mahelova J, Salačova M, et al. Human papillomavirus genotype distribution in Czech women and men with diseases etiologically linked to HPV. PLoS One. 2011; 6(7): 21913. Go to original source...
    5. McCluggage WG. New developments in endocervical glandular lesions. Histopathology. 2013; 1: 138-160. Go to original source... Go to PubMed...
    6. Robová H, Rob, L, Pluta M, et al. Guideline gynekologických zhoubných nádorů: Standard - komplexní léčba časných stadií zhoubných nádorů děložního hrdla. Guideline C53 2013, www.onkogynekologie.com.
    7. Querleu D, Morrow CP. Classification of radical hysterectomy. Lancet Oncol. 2008; 9(3): 297-303. Go to original source... Go to PubMed...
    8. Kesic V. Management of cervical cancer. Europ J Surg Oncol: 2006; 32(8): 832-837. Go to original source... Go to PubMed...
    9. Chen HS, Sheen-Chen SM. Total pelvic exenteration for primary local advanced colorectal cancer. J. Surg. 2001; 25: 1546-1549. Go to original source... Go to PubMed...
    10. Šlampa P, a kol. Radiační onkologie v praxi. 2011, 3. vydání, Brno, Masarykův onkologický ústav, s.: 148-155.
    11. Long III HJ, Bundy BN, Grendys Jr. EC, et al. Randomized phase III trial of cisplatin with or without topotecan in carcinoma of the uterine cervix: a Gynecologic Oncology Group study, J. Clin. Oncol., 2005; 23: 4629-4633. Go to original source... Go to PubMed...
    12. Monk B J, Sill MW, McMeekin DS, et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent or persistent cervical carcinoma: a Gynecologic Oncology Group study. J. Clin. Oncol., 2009; 27(28): 4649-4655. Go to original source... Go to PubMed...
    13. Robova H, Halaska V, Pluta M, et al. The role of neoadjuvant chemotherapy and surgery in cervical cancer. Int J. Gynecol Cancer, 2010; 20(Suppl2): S42-S46. Go to original source... Go to PubMed...
    14. Tewari KS, et al. Improved Survival with Bevacizumab in Advanced Cervical Cancer. N Engl J Med 2014; 370: 734-743. Go to original source... Go to PubMed...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.